Genzyme
美國Genzyme Corporation www.genzyme.com
美國Genzyme公司創立于1981年，是一家全球性生物技術公司。在28個國家有超過5000名員工，已經在80多個國家開展銷售和市場推廣。
美國健贊公司（Genzyme Corporation， NASDAQ: GENZ)是全球較早成立的前十大生物制藥公司，也是前二十大納斯達克上市公司。其銷售產值排全球前十位，是生物制藥領域的五大企業之一。作為當今世界知名生物技術公司之一，健贊致力于研究和治療患有嚴重疾病的病人。于1981年成立于波士頓，現已成長為年收入超過30億美元，全球超過8000名員工的多樣化企業。一直致力于發展和應用生命科學中最先進的技術以服務于醫學的需要。它所生產的產品和提供的醫學服務救助著超過80個國家的患者，其產品主要集中于罕見遺傳病、腎病、骨關節炎、免疫系統疾病和診斷測試。健贊公司至今仍在不斷創新，繼續研究開發基因遺傳、免疫系統疾病、心臟病和癌癥等病癥。
2011年法國賽諾菲-安萬特(Sanofi-Aventis)201億美元收購健贊(Genzyme)
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
With many established products and services helping patients in nearly 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.
